Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 17, 2021
Genetics, Pharmaceutical, Health, RNA, Financial compensation, Company, NASDAQ, RNA interference, Gene, Gene silencing, Therapy, Arrowhead Pharmaceuticals, Twitter, Employment, News, Arrowhead, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 14, 2021, the Compensation Committee of the Companys Board of Directors approved inducement grants to 24 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 14, 2021, the Compensation Committee of the Companys Board of Directors approved inducement grants to 24 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The grants entitle employees, in aggregate, to receive up to 87,000 restricted stock units.
  • The grants are outside the Companys stockholder-approved equity incentive plans and vest annually over four years.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

Retrieved on: 
Tuesday, November 30, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Private Securities Litigation Reform Act, Security (finance), News, Safety, Annual report, Arrowhead Pharmaceuticals, Company, Gene silencing, Mission statement, MD, MBA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Investor, U.S. Securities and Exchange Commission, RNA interference, Therapy, COVID-19, Arrowhead, Twitter, RNA, NASDAQ, Gene, Pharmaceutical industry

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Key Points: 
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
  • Any statements contained in this release except for historical information may be deemed to be forward-looking statements.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Patient, Private Securities Litigation Reform Act, Alcoholic hepatitis, Security (finance), Liver disease, News, CEO, Mace Head Atmospheric Research Station, Safety, Sale, Organic acid, Annual report, Arrowhead Pharmaceuticals, Institute of Liver and Biliary Sciences, Hart–Scott–Rodino Antitrust Improvements Act, Mission statement, Hormone, The New England Journal of Medicine, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Pharmacokinetics, U.S. Securities and Exchange Commission, Metabolism, COVID-19, GSK, Arrowhead, Cirrhosis, SVP, ALT, Mutation, HSD17B13, GlaxoSmithKline, RNA, RNA transfection, NASH, China, RNA interference, Medicine, Fatty liver disease, Fibrosis, HSD, ARO, NASDAQ, Liver, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) under which GSK will develop and commercialize ARO-HSD, Arrowheads investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis (NASH).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) under which GSK will develop and commercialize ARO-HSD, Arrowheads investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis (NASH).
  • GSK has a global reach and impressive capabilities in the clinical development and commercialization of important medicines.
  • We look forward to enabling GSK to advance ARO-HSD towards the millions of patients worldwide who do not have adequate treatment options.
  • GSK will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead.

Arrowhead Announces JNJ-75220795 in Development for NASH

Retrieved on: 
Wednesday, November 17, 2021
Health, Infectious Diseases, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Patient, Security (finance), News, Trial of the century, Safety, Annual report, Arrowhead Pharmaceuticals, Company, Janssen Pharmaceuticals, Gene silencing, Mission statement, Fatty liver disease, Johnson & Johnson, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., U.S. Securities and Exchange Commission, RNA interference, Therapy, COVID-19, Arrowhead, Sirna, Janssen, Twitter, PNPLA3, RNA, NASH, NASDAQ, Gene, Liver, Pharmaceutical industry

PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the common I148M mutation.

Key Points: 
  • PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the common I148M mutation.
  • Arrowhead entered into a research collaboration and option agreement with Janssen in October 2018, which resulted in collaboration on JNJ-75220795.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Membrane protein, Safety, RNA interference, Sirna, American Association, Private Securities Litigation Reform Act, News, Investor, CHB, HBV, HBsAg, Security (finance), NASDAQ, RNA, Gene, Mission statement, AASLD, COVID-19, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Gene silencing, Annual report, Janssen Pharmaceuticals, ALT, Association, Arrowhead Pharmaceuticals, Twitter, Hepatitis B virus, Patient, Company, U.S. Securities and Exchange Commission, Annual general meeting, Week, Therapy, Johnson & Johnson, Janssen, Liver disease, Arrowhead, NA, HBeAg, Pharmaceutical industry, Vaccine

The data were presented in a late breaking oral presentation at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD).

Key Points: 
  • The data were presented in a late breaking oral presentation at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
  • JNJ-3989 is an investigational small interfering RNA (siRNA) that targets all hepatitis B virus (HBV) RNAs, thereby reducing levels of all viral proteins.
  • Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize JNJ-3989.
  • Patients were required to have HBsAg levels greater than 100 IU/mL to enter the study.

Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021

Retrieved on: 
Monday, November 15, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, Safety, RNA interference, Private Securities Litigation Reform Act, AHA, News, Investor, Security (finance), American Heart Association, NASDAQ, HTG, RNA, TG, Gene, Mission statement, COVID-19, Triglyceride, Gene silencing, Annual report, Merrell Dow Pharmaceuticals Inc. v. Thompson, Arrowhead Pharmaceuticals, Twitter, FCS, Company, U.S. Securities and Exchange Commission, Therapy, APOC3, Hypertriglyceridemia, Arrowhead, Patient, MCM, Pharmaceutical industry

Since similar responses were observed among MCM pts, results were pooled across dose levels.

Key Points: 
  • Since similar responses were observed among MCM pts, results were pooled across dose levels.
  • Maximal mean and median changes from baseline for APOC3, triglycerides (TG), non-HDL-C, and HDL-C were reported.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting

Retrieved on: 
Friday, November 12, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, SEQUOIA, Safety, RNA interference, American Association, Private Securities Litigation Reform Act, OLE, News, Investor, Takeda Pharmaceutical Company, Takeda, Security (finance), NASDAQ, RNA, Gene, Liver disease, F3, Mission statement, AASLD, COVID-19, GGT, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., AATD, Gene silencing, Annual report, ALT, Association, Arrowhead Pharmaceuticals, Twitter, Company, U.S. Securities and Exchange Commission, Annual general meeting, Therapy, Cirrhosis, Arrowhead, Patient, Poster, Pharmaceutical industry

The data were presented in a late-breaking poster at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), taking place November 12-15, 2021.

Key Points: 
  • The data were presented in a late-breaking poster at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), taking place November 12-15, 2021.
  • In October 2020, Arrowhead and Takeda Pharmaceutical Company Limited announced a collaboration and licensing agreement to develop ARO-AAT.
  • Under the terms of the agreement, Arrowhead and Takeda will co-develop ARO-AAT which, if approved, will be co-commercialized in the U.S. under a 50/50 profit-sharing structure.
  • Arrowhead will receive an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million.

Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting

Retrieved on: 
Friday, November 12, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, ARO, Fatty liver disease, Safety, RNA interference, American Association, Hormone, Private Securities Litigation Reform Act, Organic acid, News, The New England Journal of Medicine, Investor, Cirrhosis, Security (finance), NASDAQ, RNA, Gene, TA, Mission statement, Trial of the century, Mutation, AASLD, COVID-19, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Gene silencing, Annual report, Alcoholic hepatitis, Institute of Liver and Biliary Sciences, Association, Arrowhead Pharmaceuticals, Twitter, HSD, NASH, Company, U.S. Securities and Exchange Commission, Annual general meeting, Metabolism, Therapy, Pharmacodynamics, Hospital, Pharmacokinetics, PNPLA3, Liver disease, Arrowhead, Patient, Poster, HSD17B13, Pharmaceutical industry, Vaccine

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).
  • The data were presented in a late-breaking poster at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), taking place November 12-15, 2021.
  • ARO-HSD is an investigational RNAi therapeutic targeting HSD17B13 as a potential treatment for patients with alcohol-related and nonalcohol related liver diseases, such as NASH.
  • Additional exploratory objectives of AROHSD1001 include the assessment of various measures of drug activity using liver biopsy.

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results

Retrieved on: 
Monday, November 1, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Safety, Private Securities Litigation Reform Act, Gene, Arrowhead Pharmaceuticals, Gene silencing, Twitter, RNA interference, Security (finance), U.S. Securities and Exchange Commission, NASDAQ, RNA, Conference, Annual report, Company, Webcast, COVID-19, News, Mission statement, Arrowhead, Merrell Dow Pharmaceuticals Inc. v. Thompson, Therapy, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 22, 2021, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 22, 2021, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal year ended September 30, 2021.
  • The forward-looking statements in the webcast speak only as of the original date of the webcast.
  • We assume no obligation to update or revise forward-looking statements contained in the webcast to reflect new events or circumstances.

Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences

Retrieved on: 
Monday, November 1, 2021
Health, Infectious Diseases, Genetics, Pharmaceutical, Cardiology, Biotechnology, Safety, Private Securities Litigation Reform Act, Annual general meeting, AASLD, Gene, Association, Arrowhead Pharmaceuticals, American Association, Gene silencing, Twitter, RNA interference, Security (finance), U.S. Securities and Exchange Commission, NASDAQ, Investor, American Heart Association, RNA, Liver disease, Conference, AHA, Annual report, Company, COVID-19, News, Mission statement, Arrowhead, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Therapy, Animal, Pharmaceutical industry, Vaccine

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Key Points: 
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
  • Any statements contained in this release except for historical information may be deemed to be forward-looking statements.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.